Human Microbiome-based Gut Health Test and Nutrition Market Report 2023-2030

According to the latest research report, the global human microbiome-based gut health test and nutrition market is valued at US$ 110.83 Million in 2021, and it is expected to reach US$ 885.52 Million by 2030, with a CAGR of 27.2% during the forecast period of 2022-2030. By Region, North America dominated the market with a significant share in 2021.

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1221

A human gut microbiome is a group of beneficial and harmful microorganisms present in the human body's digestive tract. Many microorganisms of thousands of different species, including bacteria, fungi, parasites, and viruses, are present in the human gut. Microbiota supports the immune system by breaking down potentially toxic food compounds and synthesizing specific vitamins, and amino acids, including all B vitamins and vitamin K. Human gut health is diagnosed using gut health test kits, which use stool tests to diagnose the health and population. These tests provide personalized results as well as recommendations for additional nutritional supplements. The preservation of gut health and the proper balance of these microorganisms is crucial for immunity, physical and mental health, and other benefits.
Consumers became more aware of the importance of good immunity, gut health, and gut health testing due to the COVID-19 impact, which will drive manufacturing and research into gut microbiome nutrition.

Rapid advancements in microbiome diagnostic testing and growing awareness of the microbiota's role in disease development are expected to drive market growth over the forecast period. Also, the global Consumer Packaged Goods (CPG) companies, innovative start-ups, and biotechs will play a significant role in the global market growth. Increasing collaborations between public and private organizations is expected to witness considerable growth opportunities during the forecast period.

However, A high intake of antibiotics and other supplements is expected to hamper the global market. Understanding the gut microbiome is challenged by the broad array in human genetic composition, dietary habits, and geographic distribution across the globe.

Regionally North America is likely to witness rapid growth during the forecast period (2022-2030) due to increased demand and the massive impact of COVID-19. Companies are granted huge funds for research on live microbiome ingredients and the development of new products.

Request for Demo Sample Report: https://www.insightaceanalytic.com/request-sample/1221

The important key players are Seed Health, ResBiotic, Fitbiomics, HSK Genetech, Mybacs, Affinity DNA, Freshly fermented, Carbiotix, Troo, Verisana, Throne, Phable, Biomesight, Invivo, Neovos, Holobiome, The BioArte, Bio & Me, ISOThrive, Zarbees, Mamasselect, Hyperbiotics, Everidis, Floraster, Enfamil, Culturelle, Biogaia, Viome, Atlas Biomed, Nouri, Bayer Consumer Health, Clasado Biosciences, CometBio, Essential formulae, ExeGi, Kerry, Immune Biotech, Pendulum Therapeutics, Evolve Biosystems, Gerber, Lovebug probiotics, Mommy's Bliss, Flore, Bioms, Ombre, Biohm, Nexbiome, Finch Therapeutics, Byheart, Mybiotics, Vedanta Biosciences, Other Prominent Players

Key developments in the market:

• In Jan 2022, Unilever has associated with the gut microbiome specialists at Holobiome to identify food & drink ingredients that could have a positive effect on mental wellbeing by targeting the gut-brain axis. The research partnership between Unilever and Holobiome attempts to find specific dietary ingredients that interact with these important bacteria. The long-term goal is to use these substances in a variety of foods and beverage products across Unilever's portfolio to naturally increase levels of calming neurotransmitters in the gut, so enhancing mental health.

• In Nov 2021, Ombre raised $3M seed round for at-home microbiome tests. Ombre will emphasis on improving its existing products, supply chain, and services and home tests, gut health reports, probiotic formulations, and in-app experience.

• In Nov 2020, Cargill invested US$25m in BioGaia, microbiome collaborations to follow and to accelerate growth and expand microbiome solutions. Cargill Health Technologies (CHT) will benefit from the investment as it expands its offering of health solutions for consumers.

• In Dec 2019, RB and Evolve BioSystems Team Up to Advance Infant Gut Health to sell 'Evivo', which is clinically proven to reduce gut pH, thereby helping suppress the growth of pathogenic bacteria in the infant's gut.

Get Report Details @ https://www.insightaceanalytic.com/report/global-human-microbiome-based-gut-health-test-and-nutrition-market/1221

Market Segmentation

Global Human Microbiome-based Gut Health Test and Nutrition Market, by Products, 2022-2030 (Value US$ Mn)
• D2C Gut Health Test
• Probiotic Supplements
• Personalized Nutrition
• Microbiome Modulators
o Ingredients
o Medical Foods
o Therapeutics

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com

This release was published on openPR.